Innovent Biologics Technology Limited
Clinical trials sponsored by Innovent Biologics Technology Limited, explained in plain language.
A Chinese biopharmaceutical company developing and commercializing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection shows promise for Diabetes-Related vision loss Results expected Dec 2026 (estimated)
- New hope for advanced tumors? early trial of IBI3026 begins Results expected Dec 2026 (estimated)
- Could a new pill beat the standard for gout? large trial underway Results expected Apr 2027 (estimated)
-
New hope for advanced tumors? early trial of IBI3026 begins
Disease control Recruiting nowThis early-phase study tests a new drug called IBI3026 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and check for side effects. About 300 participants will take part across multiple centers.
Early phase 1 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New shot for wet AMD aims to save sight
Disease control Recruiting nowThis study tests a new drug called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent further vision decline over 52 weeks. About 800 adults aged 50 and older with act…
Phase 2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC